CICERO A F G ET AL: "Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates", BIOMEDICINE & PHARMACOTHERAPY, ELSEVIER, FR, vol. 59, no. 6, 1 July 2005 (2005-07-01), pages 312-317, XP027640153, ISSN: 0753-3322 [retrieved on 2005-07-01] (B1)

ISER J H ET AL: "Resistance to chenodeoxycholic acid (CDCA) treatment in obese patients with gall stones", BMJ. BRITISH MEDICAL JOURNAL, LONDON, GB, vol. 1, no. 6126, 10 June 1978 (1978-06-10), pages 1509-1512, XP009535135, ISSN: 0959-8146, DOI: 10.1136/BMJ.1.6126.1509 (B1)

US-A1- 2017 340 589 (B1)

JORDAN GOLDSTEIN ET AL: "Novel and emerging therapies for cholestatic liver diseases", LIVER INTERNATIONAL, vol. 38, no. 9, 14 May 2018 (2018-05-14), pages 1520-1535, XP055723757, GB ISSN: 1478-3223, DOI: 10.1111/liv.13880 (B1)

MARINA G. SILVEIRA ET AL: "Investigational drugs in phase II clinical trials for primary biliary cholangitis", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 26, no. 10, 31 August 2017 (2017-08-31), pages 1115-1121, XP055523264, UK ISSN: 1354-3784, DOI: 10.1080/13543784.2017.1371135 (B1)

JONES DAVID ET AL: "Seladelpar (MBX-8025), a selective PPAR-Î agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study", THE LANCET - GASTROENTEROLOGY & HEPATOLOGY, ELSEVIER, US , vol. 2, no. 10 30 September 2017 (2017-09-30), pages 716-726, XP009530038, ISSN: 2468-1253, DOI: 10.1016/S2468-1253(17)30246-7 Retrieved from the Internet: URL:https://api.elsevier.com/content/artic le/PII:S2468125317302467?httpAccept=text/p lain [retrieved on 2017-08-14] cited in the application (B1)